Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Visilizumab dose-finding study in severe steroid-refractory ulcerative colitis
ISRCTN94152325Phase 2Completed
- Sponsor
- PDL BioPharma
- Start
- Jul 2003
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial of visilizumab in autoimmune colitis (4 arms), sponsored by PDL BioPharma. Primary endpoint: Safety and tolerability of visilizumab. Started Jul 2003; status: completed.
02
Drugs
visilizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on ISRCTN94152325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN94152325.